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In Eurotransplant kidney allocation system (ETKAS), candidates can be
considered unlimitedly for repeated re-transplantation. Data on outcome
and benefit are indeterminate. We performed a retrospective 15-year
patient and graft outcome data analysis from 1464 recipients of a third or
fourth or higher sequential deceased donor renal transplantation (DDRT)
from 42 transplant centers. Repeated re-DDRT recipients were younger
(mean 43.0 vs. 50.2 years) compared to first DDRT recipients. They
received grafts with more favorable HLA matches (89.0% vs. 84.5%) but
thereby no statistically significant improvement of patient and graft out-
come was found as comparatively demonstrated in 1st DDRT. In the mul-
tivariate modeling accounting for confounding factors, mortality and graft
loss after 3rd and ≥4th DDRT (P < 0.001 each) and death with function-
ing graft (DwFG) after 3rd DDRT (P = 0.001) were higher as compared to
1st DDRT. The incidence of primary nonfunction (PNF) was also signifi-
cantly higher in re-DDRT (12.7%) than in 1st DDRT (7.1%; P < 0.001).
Facing organ shortage, increasing waiting time, and considerable mortality
on dialysis, we question the current policy of repeated re-DDRT. The data
from this survey propose better HLA matching in first DDRT and second
DDRT and careful selection of candidates, especially for ≥4th DDRT.
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Kidney transplantation increases recipient survival and
quality of life in patients suffering from end-stage renal
disease (ESRD) [1]. Furthermore, graft and patient sur-
vival after deceased donor renal transplantation (DDRT)
continuously improved over the last decades. Numerous
investigations compared the outcome of re-transplanta-
tion with the continuation of dialysis after failure of the
first graft and clearly demonstrated the benefit of re-
DDRT for patients [2–4] and socio-economic consider-
ations [5,6]. However, any advantages of repeated re-
DDRT (third, fourth kidney transplant) remain unclear
due to scarce data.
In the Eurotransplant (ET) area, the number of
patients being re-waitlisted after returning to dialysis
steadily ranges between 17.9% and 18.9% [7]. Mortal-
ity in these patients has been reported to be high, and
re-transplantation is therefore recommended [2–4].
The outcome of re-DDRT has improved significantly
because of better panel reactive antibody (PRA) screen-
ing, crossmatching, HLA matching, postoperative
management, and immunosuppression protocols [8,9].
The outcome of a second graft has been reported to
be similar to first DDRT [8,10]. The longest survival
of a secondary graft was observed in recipients with a
graft survival of the first kidney of more than three
years [11]. Nephrologists are recommended to evaluate
re-transplantation as soon as possible after return to
dialysis, even in elderly candidates [12]. However, the
number of immunized re-listed patients on the waiting
list grows and aggravates organ shortage, which could
be assumed to push transplant physicians to accept
marginal and unsatisfyingly matched organs with scien-
tifically proven minor outcome and early graft loss
[13]. Furthermore, repeated re-DDRT inevitably leads
to complex and high-level immunization of the
patients [14,15]. Additionally, recipients with previ-
ously failed grafts frequently have a long history of
comorbidities, side effects of long-term immunosup-
pression, and numerous surgical interventions with an
increased risk of technical problems during re-trans-
plantation, all associated with reduced outcome
[8,16,17].
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To alleviate this vicious cycle of repeated re-DDRT, it
might be necessary to adjust allocation policy and possi-
bly restrict repeated re-DDRT in order to allocate kid-
neys to more promising donor–recipient constellations.
Whereas outcome of repeated re-transplantation has
been analyzed in the UNOS/OPTN area and some sin-
gle-transplant centers [16,18–25], there exists no com-
prehensive analysis on the respective collective of
repeated re-DDRT recipients in the Eurotransplant Kid-
ney Allocation System (ETKAS) and Eurotransplant
Senior Program (ESP).
Eurotransplant kidney allocation system was first
introduced in 1996 [26] and thereafter continuously
refined to improve patient and graft outcome based on
medical and immunological criteria and to streamline
use of available donor organs. DDRT allocation is based
on histocompatibility, waiting time, sensitization, logis-
tic aspects with the objective of minimizing ischemia
time, a child bonus, and medical urgency [27,28]. The
ESP started in 1999 to meet the problem of increasing
numbers of both older donors and recipients. ESP allo-
cation directs kidneys from postmortem donors of
≥65 years to recipients of ≥65 years without HLA
matching and aims at short cold ischemia times by
regional allocation [29]. Both ETKAS and ESP admit
immunologically sensitized candidates [29]. Hitherto,
neither the number of transplants received nor expected
graft or patient survival is part of the allocation algo-
rithms.
This study analyses the outcome of repeated re-
DDRT (3rd and ≥4th transplants) from 42 kidney trans-
plant centers in comparison with the results from 1st
DDRT within the ET area.
Patients and methods
The long-term outcome of repeated kidney only re-
transplantation from brain death deceased donors
within ETKAS and ESP in the ET area between 1996
and 2010 was investigated. In this time period, all trans-
plant centers within the ET area performed in total
45 435 DDRTs.
Data completeness at the ET registry turned out to
be unsatisfactory due to inconsistent obligation for the
transplant centers to input data. Therefore, a digitalized
questionnaire like previously performed by the ET com-
munity for another issue [30] was sent to all 65 ET
transplant centers. Outcome of 1st DDRT has previ-
ously been demonstrated to be comparable to results
after 2nd DDRT [2,4,5,8,15,31]. Therefore, and because
of the high number of cases (n = 5950) and the
impossibility to encourage transplant centers to com-
plete this huge amount of datasets, the latter patients
were excluded from our survey and the questionnaire
focused on 3rd and ≥4th DDRT only.
The request was issued between July 2013 and April
2015 and asked for sequence of organ transplantation,
date of last follow-up, graft loss and date of loss,
patient’s death and date of death, and death with func-
tioning graft (DwFG), respectively. DwFG is an appro-
priate measure to analyze the number of deaths not
associated with graft failure and therefore gives insights
into the concomitant health status of the affected recipi-
ents. Information on gender, age at transplant, HLA
match, waiting time, transplant period, and general
information on the overall ET waiting list and trans-
plantations was obtained from the ET database. Forty-
two centers (42/65; 64.6%) returned the questionnaires,
and data completeness increased markedly. For statisti-
cal analyses, all records without follow-up were removed
and noninformative censoring was assumed for all data
analyzed to cope with different follow-up times and the
problem of patients lost to follow-up [32]. Figure 1 dis-
plays the patient selection process. In 88 cases, recipi-
ents appeared repeatedly within the investigated period
and 280 donors donated both kidneys for repeated re-
DDRT patients. Last follow-up data were accomplished
in October 2017, and final mean and median follow-up
times for both 1st DDRTs and repeated re-DDRTs were
3040 and 2922 days vs. 2752 and 2496 days. Follow-up
was capped at 15 years after DDRT for the analysis.
According to ET data protection policy, all data were
anonymized for patient’s and center’s identity and
nationality at the ET registry department and then ana-
lyzed by the authors.
Comparisons of patient characteristics among groups
were performed using generalized estimating equations
(GEE) to account for dependent observations of
patients with multiple transplants or sharing the same
donor. Cumulative incidence curves were calculated for
patients’ death, DwFG, and graft loss, thereby account-
ing for the problem of competing risks between DwFG
and graft loss and dependent observations using robust
standard error estimates based on an infinitesimal jack-
knife estimate [33]. Censored patient survival and
cumulative incidence of DwFG and graft loss were com-
pared to all investigated subgroups and to all standard
ETKAS and ESP first transplantations between 1996 and
2010 (n = 38 173) whereof data were available in the
ET database (survival: n = 33 637 and DwFG/graft loss:
n = 31 263, respectively). For factors with more than
two groups, Bonferroni correction was applied to
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account for multiple pairwise comparisons. For patient
survival, Cox proportional hazards models were used
with a robust covariance matrix for the confidence
intervals accounting for dependent observations, and for
DwFG and graft loss, the Fine Gray proportional regres-
sion models were used with semiparametric random
effects for multivariate competing risk data [34,35] for
the analysis.
Multivariable models for patient survival, DwFG, and
graft loss included covariates previously identified to
affect graft failure and mortality after DDRT, such as
age and gender of recipient, waiting time, and HLA
mismatches for comparison between 1st, 3rd, and ≥4th
DDRT [36]. Additional models for analysis within
repeated re-DDRT recipients included age and gender
of the donor, cold ischemia time, PRA% at transplant,
and presence of HLA antibodies as additional con-
founding variables to the ones mentioned above.
Hazard ratios and subdistribution hazard ratios are
reported with 95% confidence intervals.
Primary nonfunction (PNF) was assumed when graft
failure was recorded within 90 days after transplantation
and before recipient’s death. These patients were then
excluded from all investigations on graft loss.
The numbers of HLA mismatches including HLA-A,
HLA-B, and HLA-DR loci were analyzed with regards
to transplant outcome. In view of pleasing results for
1st DDRTs with numerous matches, we additionally
divided all 1st DDRT and repeated re-DDRT recipients
in two groups according to the configuration of HLA
matches: all matches with at least one HLA-DR and at
least one HLA-A or one HLA-B match were assigned
for the group of “favorable matches”, and all other
matches were defined “unfavorable matches.”
Facing relevant numbers of recipients with missing
follow-up, we performed an analysis to identify sub-
groups with statistically higher rates of missing data.
Whereas no differences in patients with and without
follow-up could be revealed with regards to age, gender,
waiting time, transplant sequence, PNF, and HLA
match, more patients transplanted between 2006 and
2010 had no follow-up within the repeated re-DDRT
collective, respectively (Table 1a). For comparison,
among 1st DDRT recipients no follow-up was more fre-
quently observed in patients of younger age, female gen-
der, a good HLA match, without PNF, and
transplantation between 2001 and 2010 (Table 1b).
A two-sided level of significance of 0.05 was used for
all analyses. Statistical analysis was performed using R
version 3.6.1 (R Foundation for Statistical Computing,
Vienna, Austria) with the packages survival and timereg
[37,38]. All data ascertainments and analyses were per-
formed in accordance with ethical standards as laid
down in the Declaration of Helsinki.
Results
1st DDRT recipients were significantly older than recipi-
ents of a 3rd or ≥4th DDRT (mean age 50.2 years, SE
0.1 vs. 43.0 years, SE 0.4; P < 0.001; Fig. 2). Compar-
ison of average waiting time for repeated re-DDRTs ver-
sus 1st DDRT revealed no significant difference
(1323.2 days, SE 30.9 vs. 1339.2 days, SE 5.1;
P = 0.792). For this subanalysis only, patients with a
waiting time less than or equal to 180 days were
excluded, assuming these short times were due to a pre-
ceding PNF, conserving waiting time for the subsequent
allocation. Mean waiting time was shorter in children
because of the pediatric bonus in ETKAS, and recipients
of ≥65 years participating in the ESP in all subgroups
investigated within this study.
Relevant basic patient demographics, transplant-
specific information, and subgroup-related transplant
outcome are outlined in Tables 2, and 3 summarizes
results for the multivariable models for patient survival
as well as the competing risks DwFG and graft loss.
After accounting for confounding variables, the mul-
tivariable models for all recipients showed significantly
worse patient and graft survival for 3rd and ≥4th DDRT
compared to 1st DDRT. Further, 3rd DDRT recipients
had a significantly higher risk of DwFG compared to
1st DDRT, whereas comparison to ≥4th DDRT was not
significant (Table 3a). The cumulative incidence curves
regarding transplant sequence for patient death, DwFG,
and graft loss are depicted in Fig. 3.
For the comparison between 3rd DDRT recipients
and ≥4th DDRT recipients the multivariate models
revealed no significant difference in DwFG and graft
loss, but patient survival was significantly worse for
≥4th DDRT compared to 3rd DDRT (P = 0.039;
Table 3b). It should be noted, that patient survival,
graft loss, and DwFG did not differ significantly in
repeated re-DDRT recipients between the three inves-
tigated time periods after accounting for the different
length of follow-up by truncating at 8 years after
DDRT (Table 2).
Older age was significantly associated with an
increased risk of patients’ death and DwFG, and with
a decreased risk of graft loss in both the models for
all recipients and repeated re-DDRT (Table 3), sup-
porting the results of the univariate analysis (Table 2;
Fig. 4).
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Finally, a significant relationship was detected
between longer cold ischemia time and increased risk
of patients’ death and DwFG as well as between
higher donor age and worse patient and graft survival
in the multivariable models for repeated re-DDRT
(Table 3b).
The incidence of PNF was significantly higher in re-
DDRT (12.7%) than in 1st DDRT (7.1%; P < 0.001).
For the latter group, younger age was positively associ-
ated with a lower rate of PNF (P < 0.001, Table 4a).
Despite lower number of HLA mismatches (Table S1)
and younger recipient age, the outcome was inferior in
Table 1. Overview on data completeness for follow-up of (a) repeated re-DDRT and (b) 1st DDRT with regard to
patient- and transplant-specific factors.
(a) Repeated re-DDRT (b) 1st DDRT
Patients with follow-up Lost to follow-up
P-value
Patients with follow-up Lost to follow-up
P-valuen % n % n % n %
Transplant sequence repeated re-DDRT
3rd transplant 956 82.3 50 79.4
≥4th transplant 206 17.7 13 20.6
Gender
Female 511 44.0 21 33.3 12 885 38.3 1210 40.4 0.025
Male 651 56.0 42 66.7 20 752 61.7 1786 59.6
Age*
0–15 years 20 1.7 1 1.6 1245 3.7 86 2.9 0.003
16–55 years 964 83.0 48 76.2 17 955 53.4 1781 59.4
56–64 years 139 12.0 11 17.5 7756 23.1 676 22.6
≥65 years 38 3.3 3 4.8 6681 19.9 453 15.1
Missing 1 0.1 0 0.0 0 0.0 0 0.0
Transplant period
1996–2000 406 34.9 13 20.6 0.022 10 596 31.5 425 14.2 <0.001
2001–2005 353 30.4 18 28.6 10 512 31.3 1303 43.5
2006–2010 403 34.7 32 50.8 12 529 37.2 1268 42.3
Waiting time
0–11 months 257 22.1 16 25.4 7789 23.2 836 27.9
12–23 months 230 19.8 11 17.5 5601 16.7 497 16.6
24–59 months 406 34.9 20 31.7 11 649 34.6 845 28.2
≥60 months 269 23.1 16 25.4 8598 25.6 818 27.3
PNF
No PNF 1015 87.3 56 88.9 31 263 92.9 2986 99.7 <0.001
PNF 147 12.7 7 11.1 2374 7.1 10 0.3
Immunulogical HLA mismatches (grouping)
Favorable match† 1033 88.9 55 87.3 28 353 84.3 2605 86.9 <0.001
Unfavorable match‡ 128 11.0 8 12.7 5197 15.5 374 12.5
Missing 1 0.1 0 0.0 87 0.3 17 0.6
Number of immunulogical HLA mismatches
0 240 20.7 13 20.6 5716 17.0 563 18.8 <0.001
1 120 10.3 8 12.7 2241 6.7 205 6.8
2 293 25.2 10 15.9 8006 23.8 745 24.9
3 311 26.8 21 33.3 10 052 29.9 918 30.6
4 137 11.8 7 11.1 4679 13.9 356 11.9
5 50 4.3 4 6.3 2140 6.4 144 4.8
6 10 0.9 0 0.0 716 2.1 47 1.6
Missing 1 0.1 0 0.0 87 0.3 18 0.6
*Age classes were chosen according to ET categorization.
†At least one HLA-DR plus at least one HLA-A or one HLA-B match.
‡No HLA-DR or neither HLA-A nor HLA-B match.
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3rd and ≥4th DDRT than in 1st DDRT recipients
(Table 3a).
The rate of “favorable matches” was significantly
higher in repeated re-DDRT compared to 1st DDRT
recipients (Table 4b; 89.0% vs. 84.5%; P < 0.001), and
“favorable matches” correlated positively with lower
recipient’s age in both 1st DDRTs (P < 0.001) and
repeated re-DDRTs (P = 0.011; Table 4b). A
Figure 1 Flowchart: Selection process of patients analysed in this study. DDRT: deceased donor renal transplantation; PNF: primary non-func-
tion (excluded for analyses of graft loss)
622 Transplant International 2020; 33: 617–631
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conspicuously high number of unfavorable matches
were found for the elderly of both 1st DDRTs (43.7%)
and re-DDRTs (21.1%) which must be assumed to be a
result of the waiver of HLA matching within the ESP.
When recipients older than 64 years were excluded
from the analysis, the difference in “favorable” matches
across age was no longer significant for 1st DDRT
recipients (P = 0.090) and repeated re-DDRTs
(P = 0.051). Finally, the impact of “favorable” versus
“nonfavorable” HLA matches on outcome was com-
pared for both 1st DDRT and repeated re-DDRT recipi-
ents. Figure 5 displays the positive effects on patient
death, DwFG, and graft loss in the 1st DDRT controls
whereas no benefit of “favorable” HLA matches could
be detected for the repeated re-recipients in the univari-
ate and multivariable analysis after accounting for con-
founding variables, just as revealed in the HLA
mismatch analysis (Tables 2 and 3; Fig. S1).
Discussion
With the booming success of transplantation, the rate
of sequential DDRTs increased over time and will do so
in the future due to better survival of recipients. How-
ever, reduced graft survival potentially results from the
demographic change toward older donors and a consec-
utively increasing number of expanded criteria donors.
As 65 ET transplant centers performed re-DDRTs,
both surgical difficulties due to precedent procedures
[16] and immunological challenges because of immu-
nization [39] do not act as a deterrent to refrain from
sequential transplantations. However, as the number of
organ donations declines and, consequentially, waiting
time increases, this policy has to be challenged. We
asked the question, whether there are data prompting
an upper limit to sequential transplantations as there
should be a balance between rate of success [8,40] and
need [7].
Demographic data of repeated re-recipients
The rate of 2.9% repeated re-DDRTs among all DDRTs
is comparable to previously published reports from
other programs [6,16,20]. Although statistically increas-
ing overall graft survival times might suggest repeated
re-DDRT to be a problem of the elderly transplant
patients, mean age in repeated re-DDRT recipients
turned out to be significantly lower compared to 1st
DDRT (Fig. 2). However, a younger mean age of re-
DDRT recipients was previously reported for the
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Figure 2 Age in years at deceased donor renal transplantation
regarding transplant sequence.
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Figure 3 Cumulative incidence
curves by transplant sequence for (a)
patient death and (b) death with
functioning graft and graft loss for
1st deceased donor renal
transplantation (DDRT) and repeated
re-DDRT.
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These findings suggest the presence of a so far
unspecified group of recipients who need a first trans-
plant early in their life, then rapidly loose grafts and
end up with repeated re-DDRTs at a median age of
43.0 years. Hypothetically, these patients can be charac-
terized in future analyses by either an altered immuno-
logical pattern or distinct underlying and concomitant
diseases or even nonadherence, all leading to early and
repeated graft loss. Unfortunately, these data are cur-
rently not reported to the ET database. Facing the con-
spicuously younger mean age of repeated re-DDRT
recipients, further analyses should be performed within
this subgroup to identify and ideally eliminate factors
that lead to repeated early graft losses. In 1st DDRT
recipients, the peak at 65 years represents the increased
allocation probability for candidates with longer waiting
times who change to the ESP and then rapidly receive a
transplant as reported before.
The observed higher rate of PNF in repeated re-
DDRT patients (Table 4a) fits into the expected pattern
of highly immunized patients who additionally suffer
from serious comorbidities. Unfortunately, the ET
database hitherto does not register any data on
comorbidities.
Survival of repeated re-recipients
Multivariable modeling accounting for confounding fac-
tors revealed significantly worse survival for 3rd and
≥4th DDRTs as compared to recipients of a 1st DDRT
contradictory to previous reports [6,16,22,25] (Table 3a;
Fig. 3a).
The outcome of ≥4th DDRTs was worse compared to
3rd DDRT (Table 3b). This observation may be due to
a higher prevalence of serious concomitant diseases,
accumulated side effects of medications and long-term
dialysis, and complications due to highly dosed
immunosuppressants.
Currently, apart from our study, there are no data
on patient survival or improvement of recipient’s
quality of life after ≥4th DDRT as compared to
patients’ outcome of continued renal replacement
therapy. Moreover, a careful selection of potentially
suited candidates registered for ≥4th DDRT can be
Table 4. (a) Primary nonfunction and (b) HLA matches regarding sequence of transplantation and age at
transplantation for 1st deceased donor renal transplantation (DDRT) and repeated re-DDRT.
P-values: 1: < 0.001; 2: 0.020; 3: 0.022; 4: <0.001 (for continous age); 5: 0.011 (for continous age).
*At least one HLA-DR plus at least one HLA-A or one HLA-B match.
†No HLA-DR or neither HLA-A nor HLA-B match.
‡Age classes were chosen according to ET categorization.
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assumed. Therefore, these findings are alarming. Death
on waiting list while waiting for a third or fourth
graft at ET is reported for 325 candidates during the
investigated period. However, the estimated number
of unreported deaths after delisting remains indeter-
minate because these data are neither systematically
reported to ET nor to the transplant centers or
another registry.
Graft loss in repeated re-recipients
In previous studies, graft survival in 3rd compared to
1st DDRT recipients was similar [20,23] or decreased
[6,16,22,25]. In our study, a significantly increased
cumulative incidence of graft loss for 3rd and ≥4th
DDRTs as compared to 1st DDRTs was identified
(Tables 2 and 3a; Fig. 3). These results can mainly be
ascribed to accelerated rejection due to immunization
and probably to an increased prevalence of comorbidi-
ties in the repeated re-DDRT group as stated above.
Especially immunization could be expected to be
higher in 3rd and ≥4th DDRT recipients. Previously,
the impact of HLA-DR mismatch and acute rejections
could be identified as relevant factors influencing graft
loss negatively even in first re-DDRT recipients [8].
During the 1990s, several developments such as the
introduction of new calcineurin inhibitors, improve-
ments in antibody screening, crossmatching and HLA
matching, advanced prophylaxis and control for infec-
tions, and more effective anti-rejection therapy influ-
enced graft survival rates positively [8]. However, all re-
recipients from this survey had similar patient survival
and cumulative incidences of DwFG and graft loss in
the three time periods investigated (Table 2).
This survey at hand first revealed the encouragingly
positive impact of “favorable” HLA matching on patient
survival, DwFG, and graft loss in 1st DDRT and next
reported on its statistical irrelevance in the repeated re-
DDRT group for the very first time in literature (Table 3;
Figs 5 and S1). Therefore, recipient-associated factors like
comorbidities and short cold ischemia times (Table 3b)
must be assumed to have much more impact on outcome
than “favorable” matching in these recipients.
Together with these findings, the significant differences
in patient survival between 3rd and ≥4th DDRT recipi-
ents on the one hand and in patient survival and DwFG
between younger and elderly repeated re-recipients on
the other hand (Tables 2 and 3; Figs 3 and 4) further
strengthen the hypothesis that not only increased immu-
nization but also side effects of therapy, health implica-
tions due to long-term renal replacement therapy,
accumulating comorbidities, and complications due to
poor organ function in the course of time lead to
repeated organ losses and death and therefore display a
severe problem especially in the ≥4th DDRT recipients.
Age-related outcome of repeated re-recipients
The analyses clearly demonstrate the significantly better
patient survival of children compared to older recipi-
ents, lower DwFG and a disastrous ten-year graft loss
(74.4%; Tables 2 and 3; Fig. 4). Previously published
studies on graft outcome in pediatric recipients demon-
strated comparably poor graft survival rates after first
kidney transplantation [31] and both first and repeated
re-DDRT [42], respectively.
Our findings strongly support the assertion that
comorbidities and accumulation of therapeutic side
P-values:
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Figure 4 Cumulative incidence curves by age group at transplantation for (a) patient death and (b) death with functioning graft and graft loss
for repeated re-DDRT.
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effects are less prevalent in children and “mid agers”
but cause death and DwFG in elderly repeated re-recipi-
ents (Fig. 4; Table 3b).
Children had significantly more favorable matches
(Table 4b), which are most likely due to restrictive in-
house regulations regarding HLA mismatches and organ
quality in most centers. Furthermore, the significantly
increased rate of unfavorable matches in seniors can
most likely be ascribed to the reduced importance of
HLA matching in the opinion of treating physicians for
this group and the waiver of HLA matching in the ESP.
The high cumulative ten-year incidence of graft loss in
pediatric recipients (74.4%; Tables 2 and 3b) despite
favorable HLA matching and graft selection is most
likely related to nonadherence as highlighted before
[43,44].
Data completeness in the Eurotransplant database
Data completeness differs between the ET member
countries. While in some countries like the Netherlands
and Belgium, data delivery to ET is compulsory; in
others like Germany, it is up to the centers. This
explains the in part suboptimal data completeness.
However, by use of statistical censoring missing follow-
up was correctly compensated for analyses of 1st DDRT
and repeated re-DDRT.
Limitations
The main limitation of this study is the retrospective
data assessment from a noncompulsory database and
the consecutively limited information. Due to the par-
ticipation of 64.6% of the ET transplant centers, data
completeness was considerable after return of the ques-
tionnaires. Nevertheless, several interesting parameters
like delayed graft function, rejection, one-year serum
creatinine level, primary renal disease, concomitant dis-
eases, and detailed features from deceased donor organs
were not available.
Another bias of this study might derive from the
fraction of patients without follow-up data as discussed
above. However, the data suggest that especially obser-
vations with favorable outcome are missing in the con-
trol group, which may result in comparatively even

















































































































































(d) Graft loss for
repeated re-DDRT
























HLA match  favourable  unfavourable  
Figure 5 Cumulative incidence curves by HLA matches at transplantation for (a) patient death and (b) death with functioning graft (DwFG)
and graft loss for 1st deceased donor renal transplantation (DDRT) and (c) patient death and (d) DwFG and graft loss for repeated re-DDRT.
628 Transplant International 2020; 33: 617–631
ª 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT
Assfalg et al.
Next, the comprehensive cohort might be inhomoge-
neous due to different therapeutic regimens in the cen-
ters. However, earliest data come from transplantations
of the year 1996 when triple therapy with calcineurin
inhibitors, mycophenolic acids, and steroids was well
established and generally accepted. Analyzing the out-
come regarding the three consecutive time periods
revealed comparable results.
Finally, to reveal the true benefit of repeated re-trans-
plantation, the outcome of repeated re-DDRT also
ought to be compared to the course of those candidates
qualifying for repeated re-DDRT after failure of their
second or third transplant but continuing dialysis. In
this ideal setting, the impact of long-term renal replace-
ment therapy and lead time on dialysis could be identi-
fied and the actual benefit of repeated re-DDRT versus
continued dialysis would be examined from the point of
view of those candidates confronted to the decision
whether to apply for another graft or not. However,
data on patients eligible for repeated re-DDRT but
abstaining from the procedure are not available at the
present time too.
Conclusions
In our study, recipients of more than two sequential
grafts had a shorter graft and patient survival than
any other group. The results emphasize the benefit of
HLA matching in first and second DDRT
[15,20,22,31,45]. Further studies should be initiated to
evaluate the expected positive impact of well-matched
first and second kidney transplantations on a reduc-
tion of repeated re-transplantations on the one hand
and a better graft survival of these 3rd and ≥4th
grafts due to lower immunization levels on the other
hand in future.
The study clearly indicates that a mandatory joined
register to collect all data on donors and recipients,
including concomitant diseases, is urgently needed to
identify those candidates who do and who do not profit
from repeated re-transplantation. Furthermore, long-
term survival of repeated re-transplantation should be
compared prospectively to continuation of dialysis.
The current and future aggravated organ shortage
and the need to balance demand with success, forces
us to look deeper into the matter and find out as
soon as possible whether a fourth graft should be
allowed in allocation. Allocation schemes should
include factors such as immunization, concomitant dis-
eases and underlying disease, a required minimum of
HLA matches, duration of organ function and
sequence of previously transplanted graft(s), nonadher-
ence, and special regulations for distinct age groups.
The long-term objective of kidney allocation could be
an algorithm including both need and promising out-
come just as the Lung Allocation Score (LAS) in lung
transplantation. However, according to distinct differ-
ences in organ donation rates, waiting times, and
death on waiting list between ET countries, the scope
for generous repeated organ allocation is rated differ-
ently. As this future kind of allocation is far more
complicated than anything around so far, its develop-
ment will take a lot of time and needs reliable data
(which are not available today). In the meantime, we
should carefully consider whether a fourth transplanta-
tion is really a useful measure.
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Figure S1. Cumulative incidence curves by number
of HLA-mismatches at transplantation for (a) patient
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death and (b) DwFG and graft loss for 1st DDRT and
(c) patient death and (d) DwFG and graft loss for
repeated re-DDRT.
Table S1. Number of HLA-mismatches of 1st DDRT
and repeated re-DDRT regarding transplant sequence
and recipients’ age at transplant.
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